Lexaria Bioscience Corp. - Common Stock (LEXX)
1.3800
0.00 (0.00%)
Lexaria Bioscience Corp is a biotechnology company that focuses on the development of its proprietary drug delivery technology, which enhances the bioavailability of active pharmaceutical ingredients
The company's primary goal is to improve the efficacy and speed of absorption for various compounds, particularly those related to cannabis and nicotine. Through its innovative methods, Lexaria aims to revolutionize the way these substances are consumed, potentially leading to more effective therapeutic outcomes and improved user experiences in the market for both recreational and medicinal products.

Via Benzinga · September 2, 2024

LEXX stock results show that Lexaria Bioscience missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024.
Via InvestorPlace · July 12, 2024

Some penny stocks can be diamonds in the rough. These A-rated penny stocks are all solid picks for a portfolio this month.
Via InvestorPlace · June 24, 2024

A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.
Via InvestorPlace · June 14, 2024

Lexaria Bioscience shares are trading lower by 6.5% Thursday morning. The company finalized agreements for a registered direct offering.
Via Benzinga · February 15, 2024

It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning!
Via InvestorPlace · June 4, 2024

Via Benzinga · June 4, 2024

For a growth investor, one of the top advantages of A-rated penny stocks is that they have the potential for oversized profits.
Via InvestorPlace · May 30, 2024

Via Benzinga · April 16, 2024

LEXX stock results show that Lexaria Bioscience beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · April 9, 2024

Via Benzinga · March 12, 2024

Via Benzinga · February 28, 2024

Shares of Asana, Inc. (NYSEASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.
Via Benzinga · March 12, 2024

Via Benzinga · February 27, 2024

Via Benzinga · February 9, 2024

Lexaria Bioscience just reported results for the first quarter of 2024.
Via InvestorPlace · January 22, 2024

Via Benzinga · November 27, 2023

Via Benzinga · November 21, 2023

Via Benzinga · July 21, 2023

Via Benzinga · May 23, 2023

Gainers
Via Benzinga · May 23, 2023

Lexaria Bioscience Corp (NASDAQLEXX) announces that its animal study HOR-A22-1 has been completed, showing significant enhancement in the oral delivery of the
Via Benzinga · May 18, 2023